Sanofi

Total investments

32

Average round size

97M

Portfolio companies

26

Rounds per year

1.60

Lead investments

10

Follow on index

0.19

Exits

7

Areas of investment
BiotechnologySoftwareArtificial IntelligenceHealth CareGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeutics

Summary

In 2004 was created Sanofi, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Paris. The venture was found in Europe in France.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2019. Comparing to the other companies, this Sanofi performs on 11 percentage points less the average number of lead investments. The increased amount of exits for fund were in 2019. The typical startup value when the investment from Sanofi is 500 millions - 1 billion dollars. The fund is generally included in less than 2 deals every year. Speaking about the real fund results, this Corporate Investor is 25 percentage points more often commits exit comparing to other organizations.

We also calculated 28 valuable employees in our database.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Sanofi, startups are often financed by Third Rock Ventures, Themelios Ventures, Research Corporation Technologies. The meaningful sponsors for the fund in investment in the same round are Casdin Capital, Virginia Tech Carilion (VTC) Innovation Fund, Verily. In the next rounds fund is usually obtained by VT Ventures, Sequoia Capital China, Redmile Group.

The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight BioNtech, Icosavax, Aetion. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Life Science, Pharmaceutical. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.

Show more

Investments analytics

Analytics

Total investments
32
Lead investments
10
Exits
7
Rounds per year
1.60
Follow on index
0.19
Investments by industry
  • Biotechnology (23)
  • Health Care (20)
  • Pharmaceutical (12)
  • Therapeutics (10)
  • Medical (8)
  • Show 25 more
Investments by region
  • United States (19)
  • Taiwan (2)
  • China (1)
  • United Kingdom (2)
  • France (3)
  • Show 2 more
Peak activity year
2024
Number of Decacorns
1
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
7
Avg. valuation at time of investment
637M
Group Appearance index
0.56
Avg. company exit year
8
Avg. multiplicator
58.74
Strategy success index
0.80

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Aide 11 Nov 2022 Seed Ontario, Toronto, Canada
Enable Injections 25 Oct 2018 Health Care, Manufacturing, Medical Device, Life Science Early Stage Venture 50M United States, Ohio, Cincinnati
Mirador Therapeutics 21 Mar 2024 Early Stage Venture 400M United States, California, San Diego
Seno Medical Instruments 19 Jun 2006 Health Care, Health Diagnostics, Medical Device Early Stage Venture 6M United States, Texas, San Antonio
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.